Abstract
Background Anemia and micronutrient deficiencies are common among people living with HIV (PLHIV). There are no current guidelines from the World Health Organization (WHO) regarding whether supplements are recommended or not. We sought to assess the practices with respect to nutritional supplementation among clinicians providing care to people living with HIV in Dar es Salaam, Tanzania.
Methods We conducted a cross-sectional survey at clinics providing care to PLHIV in Dar es Salaam, Tanzania. All healthcare workers with prescribing responsibility were invited. Self-administered questionnaires were used to collect information about participants’ demographic and professional characteristics, and their approach to making decisions regarding the prescription of nutritional interventions. Descriptive analyses regarding prescribing patterns and associated factors were done.
Results Two hundred and fifty-four clinicians participated in the survey. They were clinical officers (65%), medical assistants (21%) or medical doctors (13%), and attended to 30 patients (IQR: 10, 100) on average, per week. While the majority usually prescribed iron and multivitamin supplements (79% and 76%, respectively), only 33% usually prescribed ready-to-use therapeutic foods (RUTF). The decision to prescribe nutritional supplements were typically guided by patients’ clinical condition and laboratory test results. Pallor was the most commonly considered clinical feature across patient subgroups. Most participants commenced supplementation when hemoglobin concentration was ≤10g/dl. Clinicians who attended to between 10 and <100 patients or believed in the need for universal iron supplementation for pregnant PLHIV were more likely to prescribe iron supplements compared to counterparts who attended to <10 patients weekly or who did not believe in the need for universal iron supplementation for pregnant PLHIV respectively.
Conclusion Clinicians frequently prescribe nutritional supplements, with considerable variation in how they decide whether and how to.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study didn't recieve any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of Harvard T.H. Chan School of Public Health gave ethical approval for this work. The Tanzania National Institute of Medical Research gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Authors’ names for Pubmed indexing: Abioye AI, Siril H, Mhalu A, Ulenga N, Fawzi WW
Conflict of Interest Disclosures: None of the authors have any conflict of interest.
Funding: None
Data Availability
All data produced in the present study are available upon reasonable request to the author
Abbreviations used in text
- AIDS
- Acquired Immune Deficiency Syndrome
- ART
- Antiretroviral therapy
- BMI
- Body Mass Index
- CI
- Confidence Interval
- HAART
- Highly Active Antiretroviral Therapy
- HIV
- Human Immunodeficiency Virus
- ID
- Iron deficiency
- IDA
- Iron deficiency anemia
- IQR
- Interquartile range
- PLHIV
- People living with HIV
- RR
- Relative risk
- TB
- Tuberculosis;
